Nu­cle­us Ra­dio­Phar­ma makes Art­bio’s ra­dio­phar­ma as­sets; Mi­naris man­u­fac­tures blue­bird’s Lyf­ge­nia 

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls and more.

CD­MO Nu­cle­us Ra­dio­Phar­ma is part­ner­ing with clin­i­cal-stage com­pa­ny Art­bio to man­u­fac­ture its ra­dio­phar­ma ther­a­py AB001, which is in Phase 1 and 2 tri­als for prostate can­cer, ac­cord­ing to a Tues­day an­nounce­ment. Nu­cle­us will make Art­bio’s lead-ra­di­o­la­beled ther­a­pies in Rochester, MN, and use Art­bio’s tech­nol­o­gy, dubbed Al­phaDi­rect, to iso­late lead from raw ma­te­ri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER